Aim: Although prostate-specific antigen (PSA) is one of the best-known tumor markers used in the early diagnosis of prostate cancer, it may be insufficient in differentiating benign prostatic hyperplasia (BPH) from prostate cancer (PCa). In this study, in cases where the diagnostic power of PSA is insufficient, it was aimed to evaluate the possible diagnostic and prognostic roles of the miR-200 family (miR-200a, miR-200b, miR-200c, miR-141), which has been proven to be associated with cancer by many studies.